Adaptimmune Therapeutics PLC — Director's Dealing 2025

Feb 20, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2025-02-20

Reporting Person: Bertrand William C JR (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-20	Option to purchase Ordinary Shares	$0.10	A	1612032	Acquired	2035-02-20	Ordinary Shares (1612032)	Direct
2025-02-20	Option to purchase Ordinary Shares	$0.0013	A	1074696	Acquired		Ordinary Shares (1074696)	Direct

Footnotes

F1: The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.

F2: Exercisable as to 403,008 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 33,582 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 33,654 Ordinary Shares on February 20, 2029.

F3: The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137to GBP1.00. The actual exercise price will be the pounds sterling amount.

F4: Exercisable as to 268,674 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 268,674 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029.

F5: The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.